Ipamorelin dosage, logged exactly as the research measured it.

Read this first

This page records ipamorelin dosage the way the research records it — as doses given to animals or to volunteers in a study, never as a recommendation for any person. There is a real distinction here: a few studies measured how ipamorelin behaves in the body, but no study has established a safe or effective human dose for any everyday use.

The numbers that are solid are pharmacokinetic. In humans, ipamorelin has a terminal half-life of about 2 hours, and its growth-hormone pulse peaks near 40 minutes after a dose ^[2]. The numbers people swap online — subcutaneous microgram protocols, often paired with CJC-1295 — have no peer-reviewed human dosing basis and are described below as exactly that: anecdotal, not a protocol. Nothing here tells anyone what to take.

Doses used in the published studies

Across the literature, ipamorelin has been administered very differently depending on the model:

• Human PK/PD study: 4.21–140.45 nmol/kg IV over 15 minutes, as single doses ^[2].
• Human Phase 2 ileus RCT: 0.03 mg/kg IV twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 µg/day subcutaneously, divided three times daily for 15 days ^[4].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneally ^[5].

These are study doses tied to specific species and endpoints — not interchangeable, and not convertible into a human regimen. The rat bone study, for instance, divided its dose three times daily specifically to mimic pulsatile growth-hormone release ^[4], which is a study-design choice, not a dosing instruction.

Half-life and routes studied

The human pharmacokinetics are the most reliable dosing-adjacent numbers. Ipamorelin's terminal half-life in healthy human volunteers is about 2 hours (IV), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg; the growth-hormone response is a single discrete pulse peaking near 40 minutes ^[2]. In rats, plasma clearance is roughly 5-fold lower than for GHRP-6.

Routes studied span intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition studies — and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Oral dosing applies only to engineered ipamorelin-derived analogs; ipamorelin itself is not orally bioavailable. The ipamorelin-derived oral analog NN703 illustrates the point — it was specifically modified for oral absorption and reached about 30% bioavailability in dogs ^[10].

How much cjc-1295 ipamorelin should i take

The honest answer to how much cjc-1295 ipamorelin should i take is that no published source supports a human dose, and this site does not provide one. Community 'stack' protocols pair ipamorelin with CJC-1295 in subcutaneous microgram regimens, but those regimens have no peer-reviewed human dosing basis and rest on anecdote, not trials. The combination itself has never been tested in a controlled human study for any outcome ^[7]. What the literature offers is single-agent pharmacology — ipamorelin's ~2-hour half-life and 40-minute pulse ^[2] — not a combination dose. Anyone facing a real decision should consult a qualified professional and read the Ipamorelin references.

How to reconstitute cjc-1295 ipamorelin 5mg

On how to reconstitute cjc-1295 ipamorelin 5mg: the only general, non-prescriptive observation the research-supply literature supports is that ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling notes from the research-supply context, not a clinical preparation instruction and not a directive to prepare or inject anything. No validated human-use reconstitution protocol for a combination product exists, because no such product is approved.

Stability and handling notes

Ipamorelin's physical handling follows ordinary peptide behavior. It is supplied lyophilized and, in research settings, reconstituted with bacteriostatic water; the resulting solution is subject to degradation by heat and repeated freeze-thaw and is generally refrigerated. These observations come from the research-supply literature and describe how the material is stored and handled for laboratory purposes — they are not a clinical preparation protocol and carry no implication about human use. Because gray-market material is not subject to pharmaceutical quality assurance, the identity and purity of any given vial are unverified regardless of handling ^[3].